PersonFounderExecutive
Rachel Haurwitz
Rachel Haurwitz is the President and CEO of Caribou Biosciences, a clinical-stage biopharmaceutical company she co-founded in 2011 with Nobel laureate Jennifer Doudna and colleagues Martin Jinek and James Berger. A pioneer in CRISPR commercialization, Haurwitz earned her PhD from UC Berkeley under Doudna's mentorship — she was the first student in the lab to work on CRISPR — and pivoted from academia to industry to bring genome-editing technology to patients. Under her leadership, Caribou has developed a proprietary Cas12a-based platform (chRDNA technology) enabling precise, multiplex genome editing for off-the-shelf allogeneic CAR-T and CAR-NK cell therapies targeting blood cancers and autoimmune diseases. She also co-founded Intellia Therapeutics in 2014 and has been recognized on Forbes 30 Under 30, Fortune 40 Under 40, and featured in Walter Isaacson's bestseller 'The Code Breaker.'
crisprbiotechgenome-editingcell-therapycaribou-biosciencescar-t